Research
Molecular
ALOXE3 is activated during fasting and enhances insulin sensitivity via hepatic PPARγ.
Targeting ALOXE3 may be a viable strategy for improving insulin sensitivity in metabolic diseases.
StrongSupportsmedium confidence
Here, we demonstrate the lipoxygenase, ALOXE3, is a novel effector of the hepatic fasting response.
Why this rating
The study provides strong evidence through targeted metabolomics and genetic models.
Source
ALOXE3 is a hepatic fasting-responsive lipoxygenase that enhances insulin sensitivity via hepatic PPARγ
Cassandra B. Higgins et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2018
DOI 10.1101/267781
other
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Molecular
- QRISK decreased markedly after weight loss from 18.9 ± 2.2% to 11.2 ± 1.6%, p < 0.0001.Strong
- Normalization of 10-year cardiovascular risk and heart age is possible after substantial dietary weight loss and remission of T2DM.Strong
- The Low-Fat Plus diet resulted in a greater reduction in total cholesterol compared to the Low-Fat diet, with changes of -0.46 mmol/L (-17.6 mg/dL) versus -0.24 mmol/L (-9.2 mg/dL) respectively (P = 0.01).Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →